Norak Biosciences and Cellomics will jointly market certain high content screening and G protein-coupled receptor drug discovery technology in North America and Europe
Norak Biosciences and Cellomics have announced a North America/Europe sales and marketing agreement.
Cellomics will focus its direct sales channel on a combined offering that includes Cellomics's GPCR signaling BioApplication and Norak's Transfluor technology.
The agreement additionally provides for marketing of Norak's Transfluor technology with Cellomics's ArrayScan HCS reader and/or KineticScan HCS reader, an expansive portfolio of BioApplication software modules and HitKit HCS reagent kits, and informatics products; and co-development of future GPCR-based reagent products. Norak's Transfluor technology is a patented, universal GPCR drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against GPCR targets, whether known or orphan.
Transfluor was licensed in 1999 by Norak from technology developed at Duke University Medical Center and represents the combined research into GPCR signalling pathways over several decades by Norak's scientific founders, Marc Caron, Robert Lefkowitz, and Larry Barak.
"Cellomics has the most broadly penetrated HCS platform capable of imaging the Transfluor assay", stated Terry Willard, executive vice president at Norak.
"The primary objective is to target this installed base with Transfluor to bring this powerful GPCR drug discovery tool to instrument enabled users.
"We will also jointly target new users for our combined technologies."
